Testing for ESR1 Mutations Recommended in HR+, HER2- Metastatic Breast Cancer
Routine testing for ESR1 mutations should occur upon recurrence or progression of HR+, HER2- metastatic breast cancer, a guideline suggests.
Routine testing for ESR1 mutations should occur upon recurrence or progression of HR+, HER2- metastatic breast cancer, a guideline suggests.
A review of the literature identified interventions that may increase understanding and uptake of genetic testing for BRCA1/2 variants.
NGS can reveal targetable mutations and aid diagnosis for patients with cancer of unknown primary, a study suggests.
A multipronged initiative increased germline BRCA mutation testing for patients with ovarian cancer by 31%.
Researchers compared methods for recurrence risk assessment to determine the clinical utility of genetic risk assessment compared with clinical risk assessment.
Researchers sought to identify the challenges that patients and healthcare providers experience with understanding and using biomarker test results.
Preliminary results of a study comparing outreach methods for engaging patients in genetic risk assessment and testing are presented.
Survey study measured factors that affect levels of distress and uncertainty in a diverse population of patients undergoing multigene hereditary cancer testing.
A panel of experts agreed that men with metastatic prostate cancer may be the most appropriate candidates for comprehensive genetic testing.
New recommendations from an international consensus conference call for genetic testing of all men with metastatic prostate cancer (PCa) and those with a family history indicative of hereditary PCa and suggest strategies for genetic evaluation.